Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Santarus, Inc.    

SANTARUS, INC.
Mes dernières consult.
Most popular
SummaryNewsAnalysisCalendarCompanyFinancials 
News SummaryMost relevantAll newsSector newsTweets

Santarus, Inc. : Santarus and Pharming Announce Poster Presentation of Pivotal Clinical Data for RUCONEST (Recombinant Human C1 Esterase Inhibitor)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/25/2013 | 12:18pm CEST

SAN DIEGO & LEIDEN, Netherlands--(BUSINESS WIRE)-- Santarus, Inc. (NASDAQ: SNTS) and Pharming Group NV (NYSE Euronext: PHARM) announced that new data from a pivotal Phase III clinical study with RUCONEST® (recombinant human C1 esterase inhibitor) for the treatment of acute angioedema attacks in patients with hereditary angioedema (HAE) were featured in a poster presentation yesterday at the European Academy of Allergy and Clinical Immunology (EAACI) & World Allergy Organization (WAO) World Allergy & Asthma Congress in Milan, Italy. The data indicate that the time to beginning of relief of symptoms in patients experiencing an acute attack of HAE was statistically significantly shorter with RUCONEST compared with placebo.

"RUCONEST has the potential to be an important addition to the therapeutic options available for the treatment of acute attacks of HAE based on the encouraging clinical data observed to date," said Marc Riedl, M.D., Section Head Department of Clinical Immunology and Allergy, University of California, Los Angeles and lead author of the poster.

The poster is titled, Recombinant Human C1 Inhibitor for Treatment of Acute Attacks of Hereditary Angioedema: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. The primary endpoint and safety data from the study are summarized below:

Time to Beginning of Relief of Symptoms

Median (95% CI), minutes p-value*
Placebo (N=31) RUCONEST (N=44)
Based on Treatment Effect Questionnaire
(TEQ) (Primary Endpoint) 152 (93, -) 90 (61, 150) 0.031
Based on Visual Analog Scale (VAS)
Decrease
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANTARUS, INC.
2013 SANTARUS, INC. : Relocation Plans, Patient Enrollment, Management Appointments, ..
2013 SANTARUS, INC. : Santarus Announces Availability of Amended Tender Offer Materia..
2013 SANTARUS, INC. : Santarus Initiates Phase IIa Study with SAN-300 in Patients wit..
2013DJHBK INVESTMENTS LP 3Q 13F : Largest Purchases -2-
2013DJHBK INVESTMENTS LP 3Q 13F : Largest Purchases
2013DJHBK INVESTMENTS LP 3Q 13F : Holdings As Of Sep 30 -2-
2013DJHBK INVESTMENTS LP 3Q 13F : Holdings As Of Sep 30
2013DJHIGHBRIDGE CAPITAL MANAGEMENT 3Q 13F : Largest -2-
2013DJHIGHBRIDGE CAPITAL MANAGEMENT 3Q 13F : Largest Purchases
2013DJKINGDON CAPITAL MANAGEMENT 3Q 13F : Largest Eliminations
More news
Income Statement Evolution
Sector and Competitors
1st jan.Capitalization (M$)
SANTARUS, INC.0
BIOGEN7.82%59 575
CSL LIMITED28.08%45 880
ALEXION PHARMACEUTICALS9.03%29 773
GRIFOLS SA23.33%16 977
BIOMARIN PHARMACEUTICAL-2.32%14 183